Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys
- PMID: 25498223
- DOI: 10.1016/j.neuroscience.2014.12.003
Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys
Abstract
Tea polyphenols (TPs) are bioactive flavanol-related catechins that have been shown to protect dopaminergic (DAergic) neurons against neurotoxin-induced injury in mouse Parkinson's disease (PD) models. However, the neuroprotective efficacy of TP has not been investigated in nonhuman PD primates, which can more accurately model the neuropathology and motor impairments of human PD patients. Here, we show that oral administration of TP alleviates motor impairments and DAergic neuronal injury in the substantia nigra in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated PD monkeys, indicating an association between protection against motor deficits and preservation of DAergic neurons. We also show a significant inhibition of MPTP-induced accumulation of neurotoxic α-synuclein (α-syn) oligomers in the striatum and other brain regions, which may contribute to the neuroprotection and improved motor function conferred by TP. The association between reduced α-syn oligomerization and neuroprotection was confirmed in cultured DAergic cells. The most abundant and bioactive TP in the mixture used in vivo, (-)-epigallocatechin-3-gallate, reduced intracellular levels of α-syn oligomers in neurons treated with α-syn oligomers, 1-methyl-4-phenylpyridiniumion, or both, accompanied by increased cell viability. The present study provides the first evidence that TP can alleviate motor impairments, DAergic neuronal injury, and α-syn aggregation in nonhuman primates.
Keywords: Parkinson’s disease; dopaminergic neuronal injury; motor impairments; tea polyphenols; α-synuclein aggregation.
Copyright © 2014 IBRO. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.Neuropharmacology. 2013 Oct;73:98-110. doi: 10.1016/j.neuropharm.2013.05.025. Epub 2013 Jun 6. Neuropharmacology. 2013. PMID: 23747572
-
Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.Naunyn Schmiedebergs Arch Pharmacol. 2015 May;388(5):549-56. doi: 10.1007/s00210-015-1094-5. Epub 2015 Feb 13. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 25678053
-
Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.Brain Res. 2012 Jan 18;1433:104-13. doi: 10.1016/j.brainres.2011.11.021. Epub 2011 Nov 13. Brain Res. 2012. PMID: 22138428
-
Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.J Neural Transm (Vienna). 2018 Mar;125(3):337-363. doi: 10.1007/s00702-017-1774-z. Epub 2017 Aug 31. J Neural Transm (Vienna). 2018. PMID: 28861737 Free PMC article. Review.
-
Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.Curr Protoc Neurosci. 2020 Mar;91(1):e88. doi: 10.1002/cpns.88. Curr Protoc Neurosci. 2020. PMID: 32049438 Review.
Cited by
-
Herbal medicine and gut microbiota: exploring untapped therapeutic potential in neurodegenerative disease management.Arch Pharm Res. 2024 Feb;47(2):146-164. doi: 10.1007/s12272-023-01484-9. Epub 2024 Jan 15. Arch Pharm Res. 2024. PMID: 38225532 Free PMC article. Review.
-
Swimming training and herbal nanoformulations as natural remedies to improve sensory-motor impairment in rat midbrain tumor models: system biology, behavioral test, and experimental validation.3 Biotech. 2023 May;13(5):149. doi: 10.1007/s13205-023-03574-3. Epub 2023 Apr 29. 3 Biotech. 2023. PMID: 37131964
-
Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson's Disease.Pharmaceutics. 2023 Mar 3;15(3):839. doi: 10.3390/pharmaceutics15030839. Pharmaceutics. 2023. PMID: 36986700 Free PMC article. Review.
-
On the Chemical and Biological Characteristics of Multifunctional Compounds for the Treatment of Parkinson's Disease.Antioxidants (Basel). 2023 Jan 17;12(2):214. doi: 10.3390/antiox12020214. Antioxidants (Basel). 2023. PMID: 36829773 Free PMC article. Review.
-
Perspective: Is a Closer Interaction between Experimental and Clinical Research Paradigms in Chronic Neurodegeneration, Such as Parkinson's Disease, Necessary Again?Cells. 2022 Dec 30;12(1):157. doi: 10.3390/cells12010157. Cells. 2022. PMID: 36611955 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
